Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Halts Pursuit Of Zyvox Indication Based On Mortality Signal

Executive Summary

Pfizer will not pursue an indication for catheter-related infections for Zyvox (linezolid) after data from a Phase III trial indicated an increased risk of death among patients with the infections treated with the oxazolidinone antibiotic

You may also be interested in...



Zyvox is exceptional, PhRMA says

The Pharmaceutical Research and Manufacturers of America offers its first Clinical Trial Exceptional Service Award to Donald Batts (Michigan State University), Sharon Nachman (Stony Brook University) and Maryam Imam, an 11 year-old volunteer patient on March 14. The two researchers helped make advances in clinical trials that led to the development of Pfizer's Zyvox (linezolid) for treatment of drug-resistant bacterial infections...

Biohaven Shoots For Oral CGRP Leadership As Nurtec ODT Gains Momentum

The firm’s acute migraine treatment Nurtec ODT generated $65m in 2020 after launching a year ago. Biohaven aims for Nurtec to become the leader in what could be a $4bn-$5bn category in the US.

Merck & Co. Buys Pandion, Building Out Capability In Autoimmune Disease

Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel